Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Read more

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Read more

IPO

IPO Calliditas Therapeutics

Read more

Press releases

• Mar 4, 2019Calliditas Therapeutics to Present at March Investor Conferences
• Feb 12, 2019Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis
• Feb 7, 2019Year-end report, 2018

All press releases

Full-year 2018

On February 7, 2019 Calliditas Therapeutics published its business update for the full-year 2018.

• Report
• Presentation
• Audio cast

Read the report

Calendar

• Mar 27, 2019The Stifel Nordic Healthcare Seminar, London
• Apr 9, 2019 - Apr 10, 2019Needham Healthcare Conference in NY
• May 8, 2019Annual general meeting 2019
• May 8, 2019Interim report for the period January 1 – March 31, 2019

All events